Previous Article | Next Article 
Antimicrobial Agents and Chemotherapy, March 2001, p. 710-714, Vol. 45, No. 3
0066-4804/01/$04.00+0 DOI: 10.1128/AAC.45.3.710-714.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
IMP-4, a Novel Metallo-
-Lactamase from
Nosocomial Acinetobacter spp. Collected in Hong Kong between
1994 and 1998
Yiu-Wai
Chu,1
Mariya
Afzal-Shah,2
Elizabeth
T. S.
Houang,1,*
Marie-France I.
Palepou,2
Donald J.
Lyon,1
Neil
Woodford,2 and
David
M.
Livermore2
Department of Microbiology, Prince of Wales
Hospital, Chinese University of Hong Kong, Shatin, New Territories,
Hong Kong SAR, China,1 and Antibiotic
Resistance Monitoring and Reference Laboratory, Central Public Health
Laboratory, London NW9 5HT, United Kingdom2
Received 16 May 2000/Returned for modification 15 August
2000/Accepted 24 November 2000
 |
ABSTRACT |
Between 1994 and 1998, 97 imipenem-resistant
Acinetobacter isolates were identified at the Prince of
Wales Hospital, Hong Kong, China. A blaIMP PCR
product was obtained from 23 of 35 viable cultures; 12 isolates
belonged to genomic DNA group 3, 8 belonged to group 2 (Acinetobacter baumannii), 2 belonged to group 13TU, and 1 belonged to group 1. The blaIMP homologues were
sequenced from two isolates from genomic DNA group 2 and one isolate
each from groups 3 and 13TU. The four sequences included an identical 738-bp open reading frame, predicted to encode a polypeptide of 246 amino acids, with 95.6% homology to IMP-1 and 89.3% homology to
IMP-2. The new enzyme, designated IMP-4, was partially purified. It had
a pI of 8.0 and was strongly active against imipenem and meropenem,
with Vmax values 53 and 8% of that for
penicillin G, respectively. Strong activity was also seen against
oxyimino-aminothiazolyl cephalosporins but not against aztreonam.
Hydrolytic activity was inhibited by EDTA but not by clavulanate or
tazobactam. Carbapenem MICs for most
blaIMP-positive isolates were 4 to 32 µg/ml,
but one isolate with the intact gene was susceptible, with imipenem and
meropenem MICs of 0.25 and 0.5 µg/ml, respectively. The latter isolate did not produce the band with a pI of 8.0, and gene expression was inferred to have been lost. None of the isolates studied in detail
contained extrachromosomal DNA, and carbapenem resistance was not
transmissible to Escherichia coli. Nevertheless, the
presence of blaIMP-4 in different genomic DNA
groups implies horizontal transfer, and sequences resembling a GTTRRRY
integrase-dependent recombination motif were identified in the flanking
regions of blaIMP-4.
 |
INTRODUCTION |
Acinetobacter spp. are
important opportunistic pathogens, with Acinetobacter
baumannii being the predominant species in clinical settings.
Infection can involve virtually any body site in compromised patients,
but acinetobacters are particularly associated with invasion of burn
wounds and with nosocomial pneumonias in ventilated patients
(5). The therapy of Acinetobacter infections is
complicated by multidrug resistance: aminoglycosides, extended-spectrum
cephalosporins, and fluoroquinolones were active against many
Acinetobacter isolates during the early 1980s, but many
clinical isolates are now resistant. Carbapenems have retained better
activity than other antimicrobial agents, and resistance to carbapenems
is still rare (15). Nevertheless, reports of carbapenem
resistance among Acinetobacter spp. are accumulating
steadily, with three types of mechanisms being encountered. Most
carbapenem-resistant acinetobacters have OXA-type
-lactamases with
weak activity against carbapenems; such enzymes have been found in
A. baumannii isolates from Argentina, Belgium, France, Kuwait, Scotland, Spain, and Singapore (1, 2, 3, 6, 11, 13,
24). Several of these enzymes have been sequenced and are found
to form a subgroup among class D
-lactamases, presently comprising
the OXA-23, -24, -25, -26, and -27 types (3, 6, 11). A
smaller (or less reported) group of acinetobacters owe their carbapenem
resistance to
-lactamase-independent mechanisms (8, 12,
31). Finally, resistance mediated by metallo-
-lactamases has
been reported in acinetobacters from Cuba, Italy, and Japan (9,
23, 30). The enzyme from the Italian isolates, designated IMP-2,
has 84.9% amino acid homology with IMP-1 (26), a
metallo-
-lactamase that is scattered in Pseudomonas
aeruginosa, Serratia marcescens, and acinetobacters in
Japan and that has been recorded from single isolates of
Klebsiella pneumoniae in Japan and Singapore (17, 21,
28, 29). We report here a further IMP-type
-lactamase that
confers carbapenem resistance in acinetobacters collected at the Prince
of Wales Hospital, Hong Kong, China, between 1994 and 1998.
 |
MATERIALS AND METHODS |
Strain selection and identification.
Acinetobacters were
obtained from clinical specimens at the Prince of Wales Hospital,
Shatin, Hong Kong, and all those (n = 97) reported by
the clinical diagnostic laboratory to be resistant to imipenem between
September 1994 and October 1998 were selected. This categorization was
based on the British Society for Antimicrobial Chemotherapy disk method
(33) from 1994 to 1997 and on the NCCLS disk method
(20) from January 1998 onward. Viable cultures were revived from nutrient agar slants, which had been stored at room temperature for up to 5 years. Transformation (16) was
used to confirm the genus identification, and genomic DNA groups were determined by amplified 16S rRNA gene restriction analysis (ARDRA) (10).
Antibiotics and susceptibility tests.
MICs were determined
by the British Society for Antimicrobial Chemotherapy's agar dilution
method (33). The sources of the antibiotics were as
follows: ampicillin, benzylpenicillin, cephaloridine, cephalothin,
nalidixic acid, oxacillin, and rifampin, Sigma Chemical Co. (St. Louis,
Mo.); aztreonam, Bristol-Myers Squibb (Syracuse, N.Y.); cefotaxime,
Aventis (Wembley, United Kingdom); ceftazidime and cefuroxime,
GlaxoWellcome (Stevenage, United Kingdom); clavulanic acid, SmithKline
Beecham (Brentford, United Kingdom); imipenem, Merck Sharp & Dohme
(Hoddesdon, United Kingdom); meropenem, AstraZeneca (Macclesfield,
United Kingdom); nitrocefin, BBL (Cockeysville, Md.); piperacillin and
tazobactam, Wyeth (Taplow, United Kingdom); and sulbactam, Pfizer
(Sandwich, United Kingdom).
Detection of blaIMP-related
sequences.
PCR was used to detect
blaIMP-related sequences. Each reaction mixture
(50 µl) contained 2 µl of genomic DNA, prepared by boiling a single
colony in 200 µl of sterile distilled water; 25 pmol of each of the
two primers (5'-ATG AGC AAG TTA TCT GTA TTC T [IMP11] and
5'-AGT GTG TCC CGG GCC ACC [IMP12]); 0.5 U of Taq DNA polymerase (Amersham-Pharmacia Biotech, Uppsala,
Sweden); and the reaction buffer, supplied by the manufacturer. The
mixtures were heated to 94°C for 2 min and were then subjected to 35 cycles of 94°C for 30 s, 58°C for 30 s, and 72°C for 30 s,
followed by a final extension for 3 min at 72°C.
Cloning and sequencing of the blaIMP open
reading frame.
Primers 5'-ATC CAA GCA GCA AGC GCG TTA
(IMP13) and 5'-AGG CGT GCT GCT GCA ACG ACT TGT (IMP14) were
used to amplify an 879-bp fragment containing the entire
blaIMP gene. The PCR conditions were those used
for detection of blaIMP (see above). The
fragment was then subcloned into the expression vector pT-Adv with an
AdvanTage PCR cloning kit (CLONTECH Laboratories, Palo Alto, Calif.).
Recombinant plasmids were purified from selected clones with alkaline
lysis minipreps (27). The DNA sequences and orientations
of the inserts in these plasmids were determined on an ALFexpress DNA
sequencer (Amersham Pharmacia Biotech) by using a cycle sequencing kit
(SequiTherm Excel II; Epicentre Technologies, Madison, Wis.). The
Cy-5-labeled M13 universal and reverse sequencing primers were used.
Plasmid detection, transfer, and curing.
Plasmids were
extracted for electrophoresis by alkaline lysis or by boiling of the
minipreps (27). Conjugative plasmid transfer was attempted
by plate mating with Escherichia coli K-12 J53-1 pro Nalr or J53-2 pro
Rifr as the recipients, with counterselection on Diagnostic
Sensitivity Test Agar (Oxoid, Basingstoke, United Kingdom) containing
imipenem (1 µg/ml) plus nalidixic acid or rifampin (250 µg/ml), as
appropriate. Curing was attempted by growing cultures in the presence
of ethidium bromide at 0.25 or 0.5 time the MIC, recovering the cells
on nutrient agar plates, and replica plating onto Iso-Sensitest agar
(Oxoid) with and without imipenem (2 µg/ml).
Isoelectric focusing.
Crude cell extracts were prepared by
sonicating the overnight growth from nutrient agar in 0.1 M phosphate
buffer (pH 7.0) and were clarified by centrifugation at
12,000 × g. Electrofocusing was performed at 15 W of
constant current on gels with a pH range of 3.5 to 10, prepared by the
method of Livermore and Williams (19), or on Phastgels at
pH 3.5 to 9.0 run by using on automated electrophoresis system
(Phastsystem; Amersham Pharmacia Biotech, Milton Keynes, United
Kingdom).
-Lactamase bands were located with 0.5 mM nitrocefin. In
some experiments duplicate gels were run, one of which was overlaid
with 3 mM EDTA for 10 min before being developed with nitrocefin.
Purification and characterization of IMP-4
-lactamase.
Isolate 74510 was used as a source of
-lactamase for kinetic
studies. Logarithmic-phase cells were harvested from 10 liters of
nutrient broth culture, washed, and resuspended in 10 mM sodium phosphate buffer (pH 6.8) and were then disrupted by three passes through a French pressure cell (SLM Aminco, Urbana, Ill.) at 12,000 lb/in2. After ultracentrifugation at 100,000 × g to remove the debris, the supernatant was loaded onto a column
(40 by 2.6 cm) of carboxymethyl Sephadex C-50 equilibrated with 10 mM
sodium phosphate buffer (pH 6.8). This was washed with the
equilibration buffer and was then eluted with a linear gradient of 0 to
0.5 M NaCl, also prepared in 10 mM sodium phosphate buffer (pH 6.8).
Eluent fractions were screened for activity against 0.1 mM imipenem by
spectrophotometry at 297 nm and were subjected to isoelectric focusing.
Imipenem-hydrolyzing fractions containing a single
-lactamase band
were retained at
20°C. Enzyme activity was assayed by
spectrophotometry at 37°C in 0.1 M sodium phosphate buffer (pH 6.8)
containing 0.1 mM ZnCl2. The assay wavelengths were those
listed by Livermore and Williams (19), and the kinetic
parameters were calculated from Hanes plots (s/v
versus s) of initial velocity data (v) obtained
with 10 or more different substrate (s) concentrations.
Inhibition assays with clavulanate, tazobactam, and disodium EDTA were
performed under conditions in which either (i) the enzyme was added to
a mixture of inhibitor and 1 mM benzylpenicillin or (ii) the inhibitor and enzyme were incubated for 10 min before addition of
benzylpenicillin to a concentration of 1 mM.
Nucleotide sequence accession number.
The nucleotide
sequence containing the blaIMP-4 open
reading frame has been assigned the EMBO/GenBank accession number
AF244145.
 |
RESULTS |
Confirmation of resistance and detection of
blaIMP.
Between September 1994 and October
1998, the clinical diagnostic laboratory reported 97 Acinetobacter isolates resistant to imipenem on the basis of
the results of disk diffusion tests. Of these isolates, 35 remained
viable and 23 gave 474-bp PCR products with the primers IMP11 and
IMP12. By ARDRA, 12 of the 23 blaIMP-positive isolates were found to
belong to genomic DNA group 3, eight were found to belong to group 2 (A. baumannii), two were found to belong to group 13TU, and
one was found to belong to group 1 (Acinetobacter calcoaceticus). The MICs for the
blaIMP-positive isolates are summarized in
Table 1: one isolate (isolate 116665, Table 1) was fully susceptible to both imipenem and meropenem; the
others were resistant or had reduced susceptibility compared with the susceptibilities of typical acinetobacters. Of the 12 PCR-negative isolates, 5 isolates were nevertheless confirmed to be imipenem resistant by NCCLS disk diffusion tests (20), whereas
resistance was not confirmed for the remaining seven isolates.
Sequencing of blaIMP homologues.
An
879-bp fragment was cloned from four representative PCR-positive
isolates (Table 1). These were selected (i) as two representatives from
genomic DNA groups 2 and one each from DNA groups 3 and 13TU and (ii)
as being from 4 of the 5 years in which PCR-positive isolates were
collected. Three of the organisms were resistant to imipenem and
meropenem, whereas one (isolate 116665) was the highly susceptible
organism mentioned earlier. The cloned fragments from each of the four
isolates were identical and contained the entire
blaIMP-related open reading frame and its
flanking DNA. This open reading frame comprised 738 bases with 95.5%
nucleotide identity to the blaIMP-1 nucleotide
sequence, as represented by the published sequences for P. aeruginosa (18) and S. marcescens (21). A total of 31 base differences from
blaIMP-1 were identified. These translated into
10 substitutions in the deduced amino acid sequence, designated IMP-4
(Fig. 1). The amino acid replacements reflected 11 of the base changes, whereas 20 further base changes were
silent. A total of 96 nucleotide differences (13.0% divergence) and 37 amino acid differences (15.0% divergence) were observed compared with
the nucleotide sequence of blaIMP-2 and the
amino acid sequence of its protein product, IMP-2 (Fig. 1). However, 10 of the differences from the IMP-2 protein lay in the putative signal
peptide, which comprises the first 18 amino acids in the IMP-1
-lactamase (21).

View larger version (33K):
[in this window]
[in a new window]
|
FIG. 1.
Comparison of the amino acid sequences of IMP-1, IMP-2,
IMP-3, and IMP-4 -lactamases. The 18 residues that comprise the
IMP-1 signal peptide (21) are shaded.
|
|
A GTTRRRY motif, also present upstream of
blaIMP-1 in S. marcescens isolates
(4), was similarly seen upstream of the four blaIMP-4 sequences and may be involved in
integrase-dependent recombinations (see Discussion).
Plasmid transfer, detection, and curing.
Both the alkaline
lysis and the boiling miniprep methods failed to detect plasmids in any
of the four strains used as sources of DNA for sequencing. Resistance
was not conjugatively transferred to E. coli K-12
derivatives, and attempts to cure resistance with ethidium bromide were unsuccessful.
-Lactamase characterization.
Electrofocusing was performed
with extracts of the four isolates from which
blaIMP-4 was sequenced. All except strain 116665 yielded bands with pIs of 8.0 that ceased to be detectable if the gels
were overlaid with 3 mM EDTA for 10 min before nitrocefin was added as
the reporter substrate and which therefore were deduced to be zinc
dependent (Table 1). Isolates 104680 and 74510 additionally had
-lactamases with pIs of ca. 5.7 and 7.6; isolate 127091 had a
-lactamase with a pI of ca. 7.6, and isolate 116665 had a
-lactamase with a pI of 5.4. These enzymes with pI values of 5.4, 5.7, and 7.6 were not inhibited by EDTA.
On the basis of these inhibition experiments it was deduced that the
band with a pI of 8.0 corresponded to IMP-4, and this enzyme was
purified from isolate 74510. The final preparation was free of the
-lactamases with pIs of 5.7 and 7.6 produced by the isolate and
contained only two major protein species when examined by sodium
dodecyl sulfate-polyacrylamide gel electrophoresis. One of these, which
accounted for 80% of a total protein, had a molecular mass of ca. 30 kDa and was deduced to be IMP-4; the other was considerably smaller.
This preparation of IMP-4 enzyme had a very broad spectrum of activity
(Table 2), encompassing penicillins,
cephalosporins, and carbapenems. Vmax values for imipenem and meropenem were 53 and 8% of those for benzylpenicillin, respectively, and hydrolysis of oxyimino-aminothiazolyl cephalosporins also was rapid, whereas aztreonam was stable. The 50% inhibitory concentrations of EDTA, clavulanate, and tazobactam were <0.1, 1, and
1.5 mM, respectively, when the inhibitor and enzyme were incubated
together for 10 min before addition of 1 mM benzylpenicillin as the
reporter substrate and <0.1, 0.85, and 2.7 mM, respectively, when no
preincubation was allowed before addition of substrate.
Behavior of cloned blaIMP-4 in E. coli.
One E. coli TOP10F' transformant, which
resulted from the TA cloning of the 879-bp
blaIMP-4-coding fragment from isolate 104680, was tested for imipenem susceptibility. This organism had the insert
correctly oriented with respect to the orientation of the lac promoter in the vector pT-Adv. The imipenem MIC rose
from 0.38 µg/ml in the absence of
isopropyl-
-D-thiogalactopyranoside (IPTG) to 1.5 µg/ml
in its presence, whereas IPTG had no effect on the imipenem MIC (also
0.38 µg/ml) for another transformant, which had the insert in the
reverse orientation with respect to the orientation of the
lac promoter. An analogous effect was seen for meropenem in
disk diffusion tests, but this was not investigated in detail.
 |
DISCUSSION |
Carbapenem resistance in Acinetobacter spp. is an
emerging concern and is disturbing because many nosocomial
acinetobacters are already resistant to most other antibiotics
(1, 5). The present isolates were from among
carbapenem-resistant Acinetobacter spp. at the Prince of
Wales Hospital, Hong Kong, that had been a long-standing (5-year)
problem. Of 35 recoverable isolates reported to be imipenem resistant
by the diagnostic laboratory, 23 had blaIMP
homologues, 5 were confirmed to be imipenem resistant but lacked
blaIMP and 7 lacked or had lost their
resistance. Sequencing of the blaIMP homologues
from four representative PCR-positive isolates revealed that they had
blaIMP-4, a new variant in the growing
blaIMP family. The imipenem-resistant isolates
that failed to give PCR products remain to be investigated further.
After discounting the 18 N-terminal residues, which are believed to
constitute a signal peptide (21), the deduced sequence for
the mature blaIMP-4 product had 95.6% amino
acid homology to the amino acid sequence of the IMP-1 enzyme and 89.3%
homology to that of the IMP-2 enzyme. The six residues that are
believed to hold zinc ions in the active center of
metallo-
-lactamases (His 95, His 97, Asp 99, His 157, Cys 176, and
His 215 [22]) were conserved in the IMP-4 enzyme as well as in the
IMP-1, -2, and -3 enzymes. The signal peptides of IMP-1 and -4 were
also deduced to be identical, although blaIMP-4
had a silent C
T change at codon 13. IMP-2 has a substantially
different signal peptide, with 10 amino acid substitutions compared
with the sequences of both IMP-1 and -4 (26). Although all
these data indicate that IMP-4 is closer to IMP-1 than to IMP-2, the
new enzyme did share some of the amino acid changes that distinguish
IMP-2 from IMP-1, specifically, Arg(110)
Gln, Thr(133)
Lys, and
Ile(191)
Leu. IMP-3, which was recently described from Shigella
flexneri in Japan, is a minor variant of IMP-1 with two amino acid
substitutions (14).
The four isolates from which the sequence of
blaIMP-4 was confirmed were collected in 1994, 1995, 1996, and 1998, indicating long-term stability. They included
representatives of genomic DNA groups 2, 3, and 13TU (Table 1),
indicating horizontal spread; nevertheless, none of the isolates
contained detectable plasmids, and none could transfer carbapenem
resistance by conjugation. It is therefore inferred that
blaIMP-4 had become chromosomally integrated. Significantly, a GTTRRRY motif that is known to
be involved in integrase-dependent recombination was found upstream of
the blaIMP-4 reading frame, and a related
sequence was identified downstream (data not shown). The same sequence
was previously found in blaIMP-1-carrying
elements from S. marcescens in Japan (4, 18).
Transfer of blaIMP-encoding integrons among
Acinetobacter strains, with subsequent chromosomal
integration, is therefore a plausible explanation for the spread of
these genes. blaIMP-1 likewise is often
nontransmissible (28) and is inferred to become chromosomally inserted. Takahashi et al. (30) have
recently reported the transfer of a blaIMP
determinant, possibly on a plasmid, to an Acinetobacter
isolate which had lost the gene on storage.
Multiple sets of kinetic data have been published for the IMP-1 enzyme,
with relative Vmax (kcat)
rates for ampicillin, cephaloridine, and imipenem variously reported as
100, 6, and 5, respectively (18); 100, 30, and 7, respectively (21); and 100, 46, and 11, respectively
(32). This scatter may reflect assay conditions rather
than fundamental differences among the IMP enzymes. Nevertheless, it is
evident that IMP-4, like IMP-1, -2, and -3, hydrolyzes imipenem more
rapidly than it hydrolyzes meropenem, has strong activity against
oxyimino-aminothiazolyl cephalosporins and carboxy- and amino-penicillins, but spares monobactams (14, 18, 21,
32).
Expression of resistance correlated imperfectly with carriage of
blaIMP-4. Of 23 isolates positive for
blaIMP by PCR, MICs were at least 4 µg of
meropenem per ml for 22 isolates and at least 4 µg of imipenem per ml
for 20 isolates. One isolate, however, was inhibited by these
carbapenems at 0.25 or 0.5 µg/ml and thus was no less susceptible
than Acinetobacter isolates without carbapenem-hydrolyzing
-lactamases (25). This isolate (isolate 116665, Table
1) was among the four from which blaIMP-4 was
sequenced, and since no activity of the
-lactamase with a pI of 8.0 was detectable on isoelectric focusing, it is deduced that the organism
had little or no expression of its blaIMP-4
gene. Carbapenem susceptibility is also observed in some
blaIMP-1-positive P. aeruginosa
isolates from Japan (28, 29), but it is not clear whether
this behavior is because resistance demands secondary changes to
permeability (via the loss of OprD in the case of P. aeruginosa) or because blaIMP-1 is not
always expressed. Cloned blaIMP-4 gave only a very low level of imipenem resistance in E. coli, even when
it was linked to a lac promoter and induced with IPTG.
Similar results were obtained with cloned
bla-IMP-1 (21), and it seems that IMP enzymes confer carbapenem resistance only in members of the family
Enterobacteriaceae with concomitant permeability lesions.
Although the origins of the growing family of IMP
-lactamases remain
uncertain, it is evident that multiple Acinetobacter lineages with blaIMP-4 have been prevalent at
the Prince of Wales Hospital for a protracted period. This, taken
together with the growing worldwide catalogue of reports of
carbapenem-resistant acinetobacters, presents a disturbing situation.
Clinicians treating infections caused by these organisms are forced to
use ampicillin-sulbactam or cefoperazone-sulbactam so as to exploit the
inherent activity that sulbactam has against many
Acinetobacter strains (7, 31) or to use
polymyxins, which are almost universally active against Acinetobacter spp. in vitro but which have questionable
clinical efficacy.
 |
ACKNOWLEDGMENTS |
We are grateful to G. Rossolini for prepublication information on
the IMP-2
-lactamase.
The work was supported by the Research Grants Council, Hong Kong (grant
ID 4290/99M).
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Department of
Microbiology, Prince of Wales Hospital, Chinese University of Hong
Kong, Shatin, New Territories, Hong Kong SAR, China. Phone: 852 2632 2304. Fax: 852 2647 3227. E-mail: ehouang{at}cuhk.edu.hk.
 |
REFERENCES |
| 1.
|
Afzal-Shah, M., and D. M. Livermore.
1998.
Worldwide emergence of carbapenem-resistant Acinetobacter spp.
J. Antimicrob. Chemother.
41:576-577[Free Full Text].
|
| 2.
|
Afzal-Shah, M.,
H. E. Villar, and D. M. Livermore.
1999.
Biochemical characteristics of a carbapenemase from an Acinetobacter baumannii isolate collected in Buenos Aires, Argentina.
J. Antimicrob. Chemother.
43:127-131[Abstract/Free Full Text].
|
| 3.
|
Afzal-Shah, M.,
N. Woodford, and D. M. Livermore.
2001.
Characterization of OXA-25, OXA-26 and OXA-27, molecular class D -lactamases associated with carbapenem resistance in clinical isolates of Acinetobacter baumannii.
In
Antimicrob, Agents Chemother. 583-588.
|
| 4.
|
Arakawa, Y.,
M. Murakami,
K. Susuki,
H. Ito,
R. Wacharotayankun,
S. Ohsuka,
N. Kato, and M. Ohta.
1995.
A novel integron-like element carrying the metallo- -lactamase gene blaIMP.
Antimicrob. Agents Chemother.
39:1612-1615[Abstract].
|
| 5.
|
Bergogne-Berezin, E., and K. J. Towner.
1996.
Acinetobacter spp. as nosocomial pathogens: microbiological, clinical, and epidemiological features.
Clin. Microbiol. Rev.
9:148-165[Medline].
|
| 6.
|
Bou, G.,
A. Oliver, and J. Martínez-Beltrán.
2000.
OXA-24, a novel class D -lactamase with carbapenemase activity in an Acinetobacter baumannii clinical strain.
Antimicrob. Agents Chemother.
44:1556-1561[Abstract/Free Full Text].
|
| 7.
|
Brown, S.,
C. Bantar,
H. K. Young, and S. G. B. Amyes.
1998.
Limitation of Acinetobacter treatment by plasmid mediated carbapenemase ARI-2.
Lancet
351:186-187[CrossRef][Medline].
|
| 8.
|
Clark, R. B.
1996.
Imipenem resistance among Acinetobacter baumannii: association with reduced expression of a 33-36 KDa outer membrane protein.
J. Antimicrob. Chemother.
38:245-251[Abstract/Free Full Text].
|
| 9.
|
Cornaglia, G.,
M. L. Riccio,
A. Mazzariol,
L. Lauretti,
R. Fontana, and G. M. Rossolini.
1999.
Appearance of IMP-1 metallo- -lactamase in Europe.
Lancet
353:899-900[CrossRef][Medline].
|
| 10.
|
Dijkshoorn, L.,
B. Van Harsselaar,
I. Tjernberg,
P. J. Bouvet, and M. Vaneechoutte.
1998.
Evaluation of amplified ribosomal DNA restriction analysis for identification of Acinetobacter genomic species.
Syst. Appl. Microbiol.
21:33-39[Medline].
|
| 11.
|
Donald, H. M.,
W. Scaife,
S. G. B. Amyes, and H. K Young.
2000.
Sequence analysis of ARI-1, a novel OXA -lactamase, responsible for imipenem resistance in Acinetobacter baumannii 6B92.
Antimicrob. Agents Chemother.
44:196-199[Abstract/Free Full Text].
|
| 12.
|
Gehrlein, M.,
H. Leyling,
W. Cullmann,
S. Wendt, and W. Opferkuch.
1991.
Imipenem resistance in Acinetobacter baumannii is due to altered penicillin binding protein.
Chemotherapy (Basel)
37:405-412.
|
| 13.
|
Hornstein, M.,
C. Sautjeau-Rostoker,
J. Peduzzi,
A. Vessieres,
L. T. H. Hong,
M. Barthelemy,
M. Scavizzi, and R. Labia.
1997.
Oxacillin-hydrolyzing -lactamase involved in resistance to imipenem in Acinetobacter baumannii.
FEMS Microbiol. Lett.
153:333-339[Medline].
|
| 14.
|
Iyobe, S.,
H. Kusadokoro,
J. Ozaki,
N. Matsumara,
S. Minami,
S. Haruta,
T. Sawai, and K. O'Hara.
2000.
Amino acid substitutions in a variant of IMP-1 metallo- -lactamase.
Antimicrob. Agents Chemother.
44:2023-2027[Abstract/Free Full Text].
|
| 15.
|
Jones, M. E.,
C. Thornsberry,
D. M. Livermore, and D. F. Sahm.
1999.
Prevalence of Acinetobacter spp. isolates with reduced sensitivity to imipenem, as determined by a USA-wide electronic surveillance network.
J. Antimicrob. Chemother.
43:429-431[Free Full Text].
|
| 16.
|
Juni, E.
1972.
Interspecies transformation of Acinetobacter: genetic evidence for a ubiquitous genus.
J. Bacteriol.
112:917-931[Abstract/Free Full Text].
|
| 17.
|
Koh, T. H.,
G. S. Babini,
N. Woodford,
L. H. Sng,
L. M. C. Hall, and D. Livermore.
1999.
Carbapenem-hydrolysing IMP-1 -lactamase in Klebsiella pneumoniae from Singapore.
Lancet
353:2162[CrossRef][Medline].
|
| 18.
|
Laraki, N.,
M. Galleni,
I. Thamm,
M. L. Riccio,
G. Amicosante,
J. M. Frère, and G. M. Rossolini.
1999.
Structure of In31, a blaIMP-containing Pseudomonas aeruginosa integron phyletically related to In5, which carries an unusual array of gene cassettes.
Antimicrob. Agents Chemother.
43:891-901.
|
| 19.
|
Livermore, D. M., and J. D. Williams.
1996.
-Lactams: mode of action and mechanisms of bacterial resistance, p. 502-578.
In
V. Lorian (ed.), Antibiotics in laboratory medicine, 4th ed. The Williams & Wilkins Co., Baltimore, Md.
|
| 20.
|
National Committee for Clinical Laboratory Standards.
1997.
Performance standards for antimicrobial disk susceptibility tests, 6th ed. Approved standard M2-A6
National Committee for Clinical Laboratory Standards, Wayne, Pa.
|
| 21.
|
Osano, E.,
Y. Arakawa,
R. Wacharotayankun,
M. Ohta,
T. Horii,
H. Ito,
F. Yoshimura, and N. Kato.
1994.
Molecular characterization of an enterobacterial metallo- -lactamase found in a clinical isolate of Serratia marcescens that shows imipenem resistance.
Antimicrob. Agents Chemother.
38:71-78[Abstract/Free Full Text].
|
| 22.
|
Paul-Soto, R.,
R. Bauer,
J.-M. Frère,
M. Galleni,
W. Meyer-Klaucke,
H. Nolting,
G. M. Rossolini,
D. de Seny,
M. Hernandez-Valladares,
M. Zeppezauer, and H. W. Adolph.
1999.
Mono- and binuclear Zn2+ -lactamase.
J. Biol. Chem.
274:13242-13249[Abstract/Free Full Text].
|
| 23.
|
Perez, A. N.,
I. G. Bonet,
E. H. Robledo,
R. D. Abascal, and C. V. Plous.
1996.
Metallo- -lactamases in Acinetobacter calcoaceticus?
Med. Sci. Res.
24:315-317.
|
| 24.
|
Poirel, L.,
A. Karin,
A. Mercat,
I. Le Thomas,
H. Vahaboglu,
C. Richard, and P. Nordmann.
1999.
Extended-spectrum -lactamase-producing strain of Acinetobacter baumannii isolated from a patient in France.
J. Antimicrob. Chemother.
43:157-165[Free Full Text].
|
| 25.
|
Rasmussen, B. A., and K. Bush.
1997.
Carbapenem-hydrolyzing -lactamases.
Antimicrob. Agents Chemother.
41:223-232[Medline].
|
| 26.
|
Riccio, M. L.,
N. Franceschini,
L. Boschi,
B. Carravelli,
G. Cornaglia,
R. Fontana,
G Amicosante, and G. M. Rossolini.
2000.
Characterization of the metallo- -lactamase determinant of Acinetobacter baumannii AC-54/97 reveals the existence of blaIMP allelic variants carried by gene cassettes of different phylogeny.
Antimicrob. Agents Chemother.
44:1229-1235[Abstract/Free Full Text].
|
| 27.
|
Sambrook, J.,
E. F. Fritsch, and T. Maniatis.
1989.
Molecular cloning: a laboratory manual, 2nd ed.
Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.
|
| 28.
|
Senda, K.,
Y. Arakawa,
K. Nakashima,
H. Ito,
S. Ichiyama,
K. Shimokata,
N. Kato, and M. Ohta.
1996.
Multifocal outbreaks of metallo- -lactamase-producing Pseudomonas aeruginosa resistant to broad-spectrum -lactams including carbapenems.
Antimicrob. Agents Chemother.
40:349-353[Abstract].
|
| 29.
|
Senda, K.,
Y. Arakawa,
S. Ichiyama,
K. Nakashima,
H. Ito,
S. Ohsuka,
K. Shimokata,
N. Kato, and M. Ohta.
1996.
PCR detection of metallo- -lactamase gene (blaIMP) in gram-negative rods resistant to broad spectrum -lactams.
J. Clin. Microbiol.
34:2909-2913[Abstract].
|
| 30.
|
Takahashi, A.,
S. Yomoda,
I. Kobayashi,
T. Okubo,
M. Tsunoda, and S. Iyobe.
2000.
Detection of carbapenemase-producing Acinetobacter baumannii in a hospital.
J. Clin. Microbiol.
38:526-529[Abstract/Free Full Text].
|
| 31.
|
Urban, C.,
E. Go,
K. S. Meyer,
N. Mariano, and J. J. Rahal.
1995.
Interactions of sulbactam, clavulanic acid and tazobactam with penicillin-binding proteins of imipenem-resistant and -susceptible Acinetobacter baumannii.
FEMS Microbiol. Lett.
125:193-197[CrossRef].
|
| 32.
|
Watanabe, M.,
S. Iyobe,
M. Inoue, and S. Mitsuhashi.
1991.
Transferable imipenem resistance in Pseudomonas aeruginosa.
Antimicrob. Agents Chemother.
35:147-151[Abstract/Free Full Text].
|
| 33.
|
Working Party of the British Society for Antimicrobial Chemotherapy.
1991.
A guide to sensitivity testing.
J. Antimicrob. Chemother.
27(Suppl. D):1-50[Free Full Text].
|
Antimicrobial Agents and Chemotherapy, March 2001, p. 710-714, Vol. 45, No. 3
0066-4804/01/$04.00+0 DOI: 10.1128/AAC.45.3.710-714.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.